Advertisement

Ultrasound characteristics of early-stage high-grade serous ovarian cancer

      Background

      Survival from ovarian cancer is strongly dependent on the stage at diagnosis. Therefore, when confronted with a woman with an isolated adnexal mass, clinicians worry about missing the opportunity to detect cancer at an early stage. High-grade serous ovarian cancers account for 80% of ovarian cancer deaths, largely because of their tendency to be diagnosed at a late stage. Among adnexal masses, large size and the presence of solid areas on ultrasound examination have been found to be associated with cancer, but it is unclear whether these characteristics identify early-stage cases.

      Objective

      This study aimed to evaluate the ultrasound findings associated with clinically detected early-stage high-grade serous ovarian cancer.

      Study Design

      This was a retrospective cohort study of women diagnosed with stage I or II high-grade serous ovarian or fallopian tube cancer measuring at least 1 cm at pathology from 2007 to 2017. Preoperative ultrasound examinations were independently reviewed by 3 radiologists. Adnexal masses were scored for size and volume; overall appearance; presence, thickness, and vascularity of septations; morphology and vascularity of other solid components; and degree of ascites. Characteristics were compared between masses of <5 cm and larger masses and between stage I and stage II cases. Interobserver variability was assessed.

      Results

      Among 111 women identified, 4 had bilateral ovarian involvement, for a total of 115 adnexal masses characterized by ultrasound examination. The mean age at diagnosis was 61.8 years (range, 42–91 years). The median mass size was 9.6 cm (range, 2.2–23.6 cm) with 87% of cases having a mass size of ≥5 cm. A mixed cystic and solid appearance was most common (77.4%), but a completely solid appearance was more frequently seen for tumors of <5 cm compared with larger tumors (26.7% vs 13.0%). Solid components other than septations were seen in 97.4% of cases. The characteristics of stage I and II cases were similar other than ascites, which was more commonly seen in stage II cases (18.0% vs 3.1%, respectively). Interobserver concordance was high for size and volume measurements (correlation coefficients, 0.96–0.99), with moderate agreement observed across the other ultrasound characteristics (Fleiss kappa, 0.45–0.58).

      Conclusion

      In this community-based cohort, early-stage high-grade serous cancers rarely presented as masses of <5 cm or masses without solid components other than septations. Our findings provide additional support for the observation of small masses without solid areas on ultrasound examination.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • US Cancer Statistics Working Group
        US Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999-2017): US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Centers for Disease Control and Prevention.
        (Available at:)
        www.cdc.gov/cancer/dataviz
        Date: 2020
        Date accessed: January 10, 2021
        • US Department of Health and Human Services, National Institutes of Health, National Cancer Institute
        Cancer stat facts: ovary cancer.
        (Available at:)
        • Bowtell D.D.
        • Böhm S.
        • Ahmed A.A.
        • et al.
        Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
        Nat Rev Cancer. 2015; 15: 668-679
        • Henderson J.T.
        • Webber E.M.
        • Sawaya G.F.
        Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force.
        JAMA. 2018; 319: 595-606
        • Grossman D.C.
        • Curry S.J.
        • et al.
        • United States Preventive Services Task Force
        Screening for ovarian cancer: US Preventive Services Task Force recommendation statement.
        JAMA. 2018; 319: 588-594
        • Levine D.
        • Brown D.L.
        • Andreotti R.F.
        • et al.
        Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in ultrasound Consensus Conference Statement.
        Radiology. 2010; 256: 943-954
        • Amor F.
        • Alcázar J.L.
        • Vaccaro H.
        • León M.
        • Iturra A.
        GI-RADS reporting system for ultrasound evaluation of adnexal masses in clinical practice: a prospective multicenter study.
        Ultrasound Obstet Gynecol. 2011; 38: 450-455
        • Timmerman D.
        • Testa A.C.
        • Bourne T.
        • et al.
        Simple ultrasound-based rules for the diagnosis of ovarian cancer.
        Ultrasound Obstet Gynecol. 2008; 31: 681-690
        • Suh-Burgmann E.
        • Flanagan T.
        • Osinski T.
        • Alavi M.
        • Herrinton L.
        Prospective validation of a standardized ultrasonography-based ovarian cancer risk assessment system.
        Obstet Gynecol. 2018; 132: 1101-1111
        • Andreotti R.F.
        • Timmerman D.
        • Strachowski L.M.
        • et al.
        O-RADS US risk stratification and management system: a consensus guideline from the ACR ovarian-adnexal reporting and data system committee.
        Radiology. 2020; 294: 168-185
        • Sharma A.
        • Apostolidou S.
        • Burnell M.
        • et al.
        Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).
        Ultrasound Obstet Gynecol. 2012; 40: 338-344
        • Buys S.S.
        • Partridge E.
        • Black A.
        • et al.
        Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening randomized controlled trial.
        JAMA. 2011; 305: 2295-2303
        • Shih IeM.
        • Kurman R.J.
        Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
        Am J Pathol. 2004; 164: 1511-1518
        • Brown P.O.
        • Palmer C.
        The preclinical natural history of serous ovarian cancer: defining the target for early detection.
        PLoS Med. 2009; 6e1000114
        • Partridge E.E.
        • Greenlee R.T.
        • Riley T.L.
        • et al.
        Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.
        Obstet Gynecol. 2013; 121: 25-31
        • Suh-Burgmann E.
        • Hung Y.Y.
        • Kinney W.
        Outcomes from ultrasound follow-up of small complex adnexal masses in women over 50.
        Am J Obstet Gynecol. 2014; 211: 623.e1-623.e7
        • Pavlik E.J.
        • Ueland F.R.
        • Miller R.W.
        • et al.
        Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography.
        Obstet Gynecol. 2013; 122: 210-217
        • Suh-Burgmann E.J.
        • Alavi M.
        Detection of early stage ovarian cancer in a large community cohort.
        Cancer Med. 2019; 8: 7133-7140
        • Peres L.C.
        • Cushing-Haugen K.L.
        • Köbel M.
        • et al.
        Invasive epithelial ovarian cancer survival by histotype and disease stage.
        J Natl Cancer Inst. 2019; 111: 60-68